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Abstract
The Nef protein is a major determinant of pathogenicity caused by the human immunodeficiency virus (HIV) and
is encoded by the nef gene within the genomes of primate lentiviruses HIV-1, HIV-2 and simian immunodeficiency
virus (SIV). The HIV Nef protein subverts the intracellular membrane traffic to mediate endocytosis of a number of
cell surface receptors to accelerate their degradation. In this review we will examine how the multifunctional Nef can
mediate down regulation of the Major histocompatibility Complex (MHC) I complex proteins from the surface of
infected cells as a means of immune evasion by HIV. By selectively downregulating MHC-I HLA-A and HLA-B
haplotypes, while maintaining the expression of HLA-C, HLA-E and HLA-G the HIV virus is able to avoid recognition
by both the NK and cytotoxic CD8+ T cell effector responses. This protects the virus from cell lysis and enables it to
hide from the cell-mediated immune system.
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Introduction
The human immunodeficiency virus (HIV) is a major global health
issue that has claimed 39 million lives since its discovery in 1983 [1,2].
In 2013 HIV had a worldwide incidence of 2.1 million cases and a
prevalence of approximately 35 million individuals [2]. The virus arose
from cross-species transmission with HIV-1 originating from the
chimpanzee simian immunodeficiency virus (SIVcpz) and HIV-2
arising from the sooty mangabey virus (SIVsmm) [1]. As a result of the
different origins of HIV-1 and HIV-2 their nucleic acid sequences are
only 40% homologous and HIV-2 is less virulent with 98% of acquired
immunodeficiency syndrome (AIDS) cases arising from HIV-1
infection [1]. The HIV virus can be further broken down into subtypes,
with HIV-1 consisting of three subtypes: M, N and O [3]. Group M is
the most virulent and is responsible for 90% of the AIDS epidemic
worldwide with Group O and N remaining confined within Africa
[3,4].
HIV is an obligate intracellular pathogen it must gain entry into the
host and hijack its cellular machinery in order to replicate [5]. HIV is a
small RNA virus consisting of nine genes [1]. Five of these genes are
involved in viral replication and consist of gag, pol, env, tat and rev
and the other four genes nef, vpu, vif and vpr are termed accessory
proteins [1]. These accessory genes are primarily responsible for HIV’s
ability to evade the immune response and are dispensable for viral
replication [6]. Nef (negative effective factor), a 27-30 kDa
myristoylated protein, has been the most extensively researched and is
required to help the virus evade the innate and adaptive immune
defense and supports AIDS progression [5,7,8]. Nef ’s crucial role in
pathogenesis is due to its ability to markedly increase virus titres while
allowing the virus to evade the host immune response [9]. It is
expressed early in the virus life cycle and is postranslationally modified
by the irreversible attachment of myristic acid to its N-terminus
creating an important N-terminus myristolyation site that is required
to target Nef to the cellular membrane and can become
phosphorylated [10]. Nef has no demonstrable enzymatic function
[7,11]. Instead it acts as an adaptor protein by linking molecules to
specific cellular factors to propagate its downstream effects [11,12].
These effects include downregulation of CD4, retardation of the
immunological synapse and regulation of apoptosis [9,13-16]. Another
important function of Nef is its ability to downregulate major
histocompatibility complex (MHC) class I molecules and thus protects
the virus from cell-mediated and humoral immunity [17,18]. By
targeting MHC-I proteins the virus will abrogate immune recognition
and activation of by HIV-specific CD8+ T cells. Therefore, the aim of
this review was to highlight the mechanisms by which Nef
downregulates class I MHC molecules and the cellular and clinical
effects of this function.
MHC class I downregulation by Nef occurs by two different
pathways
MHC-I molecules on virally infected cells present viral antigens to
the corresponding antigen-specific CD8+ cytotoxic T lymphocytes
(CTLs) [19,20]. The processed peptide/MHC-I molecules are
assembled in the endoplasmic reticulum (ER) of the target cell and
once loaded with the viral peptide are transported to the cell surface
[21-23]. The antigen specific TCR on the CD8+CTL recognizes the
peptide/MHC-I molecule and it becomes activated and rapidly
differentiates into an effector cell that secretes perforin proteins which
assemble to form a pore in the cell membrane of the target cell and
secreted granzymes enter the cytoplasm of the target cells via the
perforin pore that results in cell lysis [17,24].
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The HIV accessory proteins Nef, Tat and Vpu (viral unique protein)
have all been linked to viral modulation of MHC-I expression [25,26].
Tat has been associated with the alteration of MHC-I transcription …
Whereas Vpu’s ability to affect MHC-I is similar to Nef in that it
downregulates surface expression albeit to a far lesser extent.
Although, Tat and Vpu have been shown to modulate MHC-I
expression Nef is the key player in HIV-1’s abrogation of this
important pathway. This is demonstrated by the fact that Nef deficient
mutants, which still express Vpu and Tat, have markedly decreased
MHC-I expression achieving only 7% of MHC-I downregulation
compared to wild type strains of HIV-1 virus. Furthermore, vpu- and
tat - deleted HIV viruses that still expressed Nef failed to significantly
downregulate MHC-I molecules [27-29].
There have been conflicting results on the mechanisms by which
MHC-I is downregulated. For example, some studies reported that
phosphatidylinositol 3-phosphate (PIP3) kinase was required for
MHC-I downregulation [30] whilst other studies reported that it was
dispensable [31]. This conflict was resolved by the understanding of
the importance of D-3 lipid phosphatase (PTEN) which
dephosphorylates phosphatidylinositol 3-phosphate (PIP3) [4]. High
levels of PIP3 present in cells that lack PTEN, such as Jurkat, CEM and
U373 T cells, prevent PACS-1 and phosphatidylinositol 3-kinase
(PI3K) inhibitors from affecting MHC-I downregulation [4,31]. This
resulted in studies proclaiming that Nef acts independently of PI3K as
the PI3K inhibitors LY294002 and wortmannin failed to inhibit Nef-
mediated MHC-I downregulation in cell lines that did not express
PTEN [31]. The rescue of PTEN expression in these cells restored the
sensitivity of MHC-I downregulation to PI3K inhibitors [4].
In addition to the requirements of PI3K, the mechanisms by which
MHC-I molecules were downregulated by nef was difficult to define.
Some debate arose on whether or not MHC-I molecules were
endocytosed or whether nef downregulated MHC-I molecules by
targeting their transport to the cell surface [32,33]. Nef can subvert
intracellular membrane traffic as part of the virus replication life cycle.
Clathrin coated vesicles mediate endocytosis and sorting from the
trans-Golgi network (TGN) and endosomes to lysosomes to mediate
protein destruction [34]. Vesicular coats are required for intracellular
membrane traffic that helps to coordinate cellular organization of
vesicles. They are composed of scaffold proteins and adaptor elements
that link the scaffold to membrane bound proteins and lipids [35].
Clathrin forms the scaffold on the vesicular coat on to which the
heterotetrameric adaptor protein (AP) complexes assemble (e.g., AP-1,
AP-2). The vesicular coat is responsible for vesicular traffic originating
from the cell membrane and TGN [34]. AP complexes help to connect
membrane proteins (i.e., cargo) to clathrin [36]. AP1 needs to be
modified by the GTPase Arf1 activator that promotes a conformational
change in the AP1 protein that allows to bind to cargo and clathrin at
the TGN [37].
The Nef and Vpu proteins of HIV help to hijack the clathrin
pathway [5,6] and are responsible for downregulating the cell surface
expression of a range of key target proteins such as CD4, MHC-I and
tetherin [38-41]. The AP1 protein plays a critical role in enabling Nef
to re-route MHC-I and tetherin from the cell surface and directs them
to lysosomes [11,42]. The cargoes carried by AP1 contain either
tyrosine based sorting signals which bind to the C terminal domain of
clathrin µ1, or dileucine signals, that bind to a site that spans the γ and
δ1 subunits of clathrin [43]. As a result Nef can hijack AP-1 to
downregulate MHC-I expression by interacting with the µ1 subunit of
clathrin via tyrosine motif binding site on its c- terminal domain [44].
In addition Nef can hijack AP-2 to downregulate CD4 via the dileucine
binding site on the clathrin α‒σ2 complex [13,45]. Both these binding
sites are normally obstructed when AP1 is in its “locked”
conformation. Therefore Nef ’s ability to subvert membrane traffic
relies on the AP1 protein being in the “unlocked” confirmation which
is linked to the GTPase activity of Arf1. Shen and colleagues have
recently shown that Nef can bind to Arf1 and this induces the
trimerization of AP-1. These trimers assembled into hexamers to help
stabilize the AP-1-Arf1 complexes and in doing so can redirect MHC-I
and tetherin to lysosomes [46].
It has now become apparent that there were two distinct pathways
of Nef-mediated MHC I downregulation [8]. They are termed the
“signalling mode” and the “stoichiometric mode” and act at distinct
temporal stages of viral infection [8]. Both pathways are dependent on
Nef ’s N-terminal myristoylation site to assemble within lipid rafts in
the plasma membrane. It appears that the “signalling mode” for MHC
modulation is utilized in response to acute infection over the first 48
hours that specifically targets the ‘mature’ MHC-I proteins that are
present at the cell surface [8], while the stoichiometric mode is a
distinct mechanism utilized by the virus after day 3 of infection and
blocks the transport of newly synthesized MHC-I proteins from the ER
to the cell surface [8,47-49]. In this way the HIV-1 virus can effectively
block immune recognition of virus infected cells by antigen-specific
CD8+ CTLs. It has been suggested that the HIV-1 virus may utilize
these different pathways to modulate MHC-I to enable it to adapt to
different cellular reservoirs. Infection of CD4+ T cells become acutely
infected with HIV-1 with a half-life of 1.5 days and during this time
the virus focuses on the signalling mode to downregulate mature
MHC-I proteins from the cell surface [8]. Once the virus has
established latency leading to chronic infection of a reservoir (e.g.
CD4+ T cells or monocytes), during this period the virus relies on the
stoichiometric mode to block transport of newly synthesized MHC-I
proteins to the cell surface.
Signalling mode
MHC-I proteins have a range of fates within the cell. Newly
synthesized MHC I proteins are loaded with peptides within the ER
and transported to the cell surface. Protein turnover directs
internalized MHC complexes to endosomes which can be targeted to
the TGN where they can be ubiquitinated and targeted for
degradation. Alternatively the MHC-I proteins may enter a recycling
pathway where they can be removed from the cell surface and be
recycled back through vesicles to cell surface. These two recycling
pathways are ubiquitous in cells and require distinct adaptor proteins
known as phosphofurin acidic cluster protein (PACS)-1 and PACS-2
[50]. PACS-1 is involved in recycling of internalized cargo proteins
from early endosomes to enable proteins to return to the cell surface
[51,52]. PACS-2 on the other hand mediates the trafficking of protein
to the ER and can also regulate the trafficking of endocytosed protein
cargoes from early endosomes to the TGN [53,54]. Both PACS proteins
are multipurpose proteins as they contain furin binding regions that
promote binding to cargo proteins, sorting adaptors and kinase
enzymes [50]. Evidence suggests that the PACS proteins mediate
distinct steps within the signalling pathway. PACS-2 is required for the
initial triggering phase and PACS-1 is for the sequestering phase of
MHC modulation [8].
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Figure 1: Functional domains on the Nef protein of HIV-1. The key
functional domains of the Nef proteins are illustrated and some of
these are described in detail within the text. The M20, EEEE65 acidic
cluster and the PXXP75 SH3 binding domain are the major
functional domains on Nef that are required for modulation of
MHC-I surface expression.
Nef has the capacity to activate a range of Src family kinases (SFKs)
including Hck, Lyn and c-Src and this property appears to be
important for HIV disease pathogenesis in animal models [55,56]. In
addition Nef can activate PI3K and this is required to block apoptosis
and to direct downregulation of MHC-I proteins from the cell surface
[30,57]. There are three motifs on the Nef protein that are crucial for its
effector activity (Figure 1). The EEEE65 acidic cluster is required for its
interaction with cytosolic sorting protein PACS-1 [58], an SH3 binding
domain motif PXXP75 enables Nef to interact with SFKs [55]. The
methionine M20 residue located at the N- terminus is critical to enable
MHC-I proteins to associate with the heterotetrameric sorting adaptor
protein AP-1 [11]. Furthermore, the D123 residue is required for Nef
to dimerize as the mutant D123G is unable to dimerize and
downregulate MHC-I [59]. These motifs are highly conserved in the M
group HIV-1 and are responsible for disease pathogenesis [60].
The “signalling mode” is the initial pathway used by the virus to
downregulate mature MHC-I molecules that are already expressed at
the cell surface of a target cell. The pathway involves two domains on
Nef, the EEEE65 acidic cluster and the PXXP75 SH3 domain binding
site, which are both located at the N-terminus of the protein
[30,58,61]. Following viral infection Nef can downregulate MHC-I by
activating an endocytic program that requires the Nef ’s acidic cluster
(EEEE62-65) to bind to the endosomal sorting protein PACS-2 and this
targets the Nef to a paranuclear region [30,61]. This change to its
cellular localization facilitates the interaction of the Nef PXXP75 SH3
binding domain to form a multiprotein complex involving Src Family
kinases (SFK)/zeta associated protein kinase 70 (ZAP70)/
phosphatidylinositol kinase 3 (PI3K) i.e. SFK/ZAP70/PI3K [4,8,62].
ZAP-70 is a SFK found in T cells that normally associates with the T
cell receptor (TCR) complex. Monocytes can be a source of HIV-1
infection due to expression of CD4 and chemokine receptors. In
monocytes the SFK Syk replaces ZAP-70 to form the protein complex
with Nef and PI3K. The SFK/ZAP-70/PI3K complex can induce
tyrosine kinase signalling and this can increase the rate of endocytosis
of cell surface MHC-I proteins from the cell surface [4,30,58]. Once the
MHC-I proteins are internalized they can be sequestered within the
paranuclear region which requires the M20 and EEEE65 domains of Nef
interacting with PACS-1 and the AP-1 protein [11,30]. The activation
of PI3K triggers the clathrin-independent, GTPase ADP ribosylation
factor 6 (ARF6)-dependent endocytosis of MHC-I molecules [8,30].
ARF6 is involved with connecting actin cytoskeletal rearrangements
with vesicle trafficking [30]. Once the MHC-I molecules are within the
ARF6 endosomes the (M20) methionine residue on Nef is required for
sequestering internalized MHC-I molecules to the TGN to prevent
further MHC-I recycling [4,30].
Stoichiometric mode
The stoichiometric mode is utilized after day 3 of infection and
affects the transport of newly synthesized MHC-I complexes to the cell
surface [8]. By 72 h post infection the stoichiometric mode is
upregulated while the signalling mode is extinguished suggesting a
temporally determined means of MHC-I downregulation [8]. It is
hypothesized that this initial latency in the stoichiometric mode is due
to the fact that sustained PI3K signalling driven by the SFK/ZAP-70/
PI3K complex is required for its initiation [8]. In contrast to the
signalling pathway, the stoichiometric mode is independent of PI3K
signalling and involves the diversion of newly synthesized MHC-I
molecules in the TGN to lysosomal compartments that is mediated by
the M20 residue on Nef /AP-1 and the process is clathrin dependent
[8,11,63]. The stoichiometric pathway is initiated when Nef binds to
the tyrosine residue at position 320 on the cytoplasmic tail of the
MHC-I molecule via its acidic cluster (EEEE65) and proline rich repeat
(PXXP72-75) [11,33,64]. As highlighted above the Nef-MHC-I complex
creates a hydrophobic region which enables the µ1 subunit of clatherin
to bind [11,65]. Once it is bound, AP-1 links clathrin to the
cytoplasmic tails of MHC molecules at the TGN and transports these
molecules to endosomes where they are tagged for lysosomal
degradation by the recruitment of β-COP [11]. A small molecular
inhibitor that prevents the SFK-Nef interaction can prevent assembly
of the SFK/Zap70/Syk-PI3K cascade and in turn can repress HIV-1-
mediated MHC-I downregulation in primary CD4+ T cells [8]. These
studies highlight the crucial role for formation of the multikinase
complex for MHC modulation and that signalling by one or more of
the kinases influences the membrane trafficking machinery that
mediates the switch between the two functional modes [8].
The importance of the MHC cytoplasmic tail in immune
evasion from NK cells and CTLs
The Nef protein has been shown to specifically target the classical
MHC-I molecules of the Human Leukocyte Antigen (HLA) complex
in particular HLA-A and HLA-B but does not affect the HLA-C, HLA-
E or HLA-G molecules [17,66,67]. The ability of Nef to bind to MHC-I
proteins is conserved across different HIV-1 M, N and O subtypes as
well as primate lentiviruses including Simian immunodeficiency
viruses (SIV) SIVcpz and SIVrcm [67]. Nef ’s ability to downregulate
the MHC-I alleles is determined by the amino acid residues within the
cytoplasmic tail of the heavy chain (Table 1). The key amino acid
residues on the cytoplasmic domain of MHC-I molecules that
facilitates Nef binding to mediate downregulation of MHC-I molecules
occur between positions 321 and 328 [17,33,44]. In HLA-A and HLA-
B molecules there is a tyrosine residue at 321 and an aspartic acid
residue at 328 whereas in HLA-C molecules there is a cysteine occupies
position 321 and asparagine at 328 [17,44] (Table 1). These amino acid
substitutions in HLA-C are sufficient to prevent the Nef molecule from
binding to the HLA-C molecule and thereby prevents its
downregulation [17]. The HLA-E molecule also inhibits Nef binding
with a substitution of glutamic acid at position 325 on its cytoplasmic
tail whereas HLA-A, -B and -C molecules contain an alanine at the
same site [17] (Table 1). Mutating the glutamic acid residue at position
325 to alanine enables the HLA-E molecule to be responsive to Nef
downregulation, demonstrating the importance of this amino acid in
inhibiting this process [17]. In contrast to the other HLA molecules,
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the HLA-G molecule evades HIV downregulation by having a
premature stop codon which results in a shorter cytoplasmic tail of just
six amino acid residues instead of the normal length of 29-33 amino
acids [66].
HLA molecule Amino acid resides at the designated positions on the
MHC proteins
HLA-A Y321 A325 D328
HLA-B Y321 A325 D328
HLA-C C321 A325 N328
HLA-E Y321 E325 D328
Table 1: The different cytoplasmic amino acid residues amongst the
four HLA haplotypes -A, -B, -C and -E. The Table shows the amino
acid residues on the different Class I HLA molecules based on the
primary amino acid sequence. The amino acid residues that Nef
requires for downregulation of classical MHC proteins (HLA A & B) to
prevent immune recognition by CD8+ T cells are represented in
normal text. The amino acid residues highlighted in bold text are those
that prevent Nef mediated MHC downregulation and therefore prevent
NK cell activation.
This differentiation between the different HLA haplotypes is
important as natural killer (NK) cells target cells can be activated in
response to limited MHC-I expression [17]. HLA-C and HLA-E inhibit
NK lysis by ligating with the inhibitory receptors on the surface of NK
cells (iNKR) [17,68]. These iNKRs are designed to protect normal host
cells from NK lysis [68]. Therefore, the maintenance of these specific
HLA proteins by Nef promotes survival of the infected cell allowing
viral replication to occur as it will avoid NK cell activation [17].
Although the majority of NK cells are inhibited by this method there is
a certain subset of NK cells that have an inhibitory receptor (NKB1)
that is specific for certain HLA-B molecules [17]. Further research is
needed to determine the role these NKB1 expressing NK cells play on
HIV disease progression. Nevertheless NK inhibition is further
compounded by the Vpu protein of HIV-1 which downregulate NTB-A
surface expression to inhibit NK degranulation [68].
In addition to NK cells, downregulation of MHC-I molecules by Nef
helps the HIV virus to evade recognition by CTLs [69,70]. Most CTL’s
are restricted to the HLA-A and HLA-B haplotypes which are targeted
by the Nef protein [17]. This is important as CTLs are recognized as an
important effector response against HIV infection and without
downregulation of MHC-I molecules the infected cells would become
susceptible to lysis by HIV-specific CTLs [69]. This selective
downregulation of MHC-I of HLA haplotypes is similar to that used by
the foetus to maintain tolerance from the maternal immune system
[71]. Interestingly, a small subset of CTLs are specific for the HLA-C or
HLA-E haplotypes [72]. Further research is needed to determine the
role that this CTL subset might have on HIV disease progression.
Clinical relevance of MHC-I downregulation
The ability of HIV-1 Nef to downregulate MHC-I is dependent on
disease progression. MHC-I downregulation is enhanced and
maintained in immunocompetent (especially asymptomatic)
individuals and lost in those that have progressed to AIDS [73]. This is
believed to be due to the high selective pressure exerted by active CTLs
in immunocompetent individuals [74].
The importance of Nef ’s ability to downregulate MHC-I molecules
in vivo and its impact on disease progression is highlighted by studies
on rhesus macaque monkeys that were infected with SIV viral strains
that carried specific mutations in the nef gene that selectively affects its
ability to downregulate MHC-I [75,76]. By mutating the Y223F residue
in the nef gene the SIVmac239 variant virus blocks MHC-I down-
regulation without affecting Nef ’s other functions such as CD4, CD28
and CD3 down-regulation and viral infectivity or viral set point load
[75]. Infection with the Y223F-Nef variant virus resulted in a chronic
viral infection but the animals remained clinically healthy at 56 weeks
post infection [75]. This is in direct contrast with rhesus monkeys that
were infected with the wild type SIVmac239 virus which had a 60 to
70% fatality rate within the first year [75]. Interestingly, the Y223F-Nef
viral variant reverted to regain its capacity to downregulate MHC-I
downregulation within 2-4 weeks post infection [75]. This coincides
with the peak in CTL response in SIV-infected macaques which occurs
at week 2 [75]. Therefore, this reversion of MHC-I downregulation is
likely due to CTL selective pressure [75]. Despite the fact that 4 weeks
post infection the virus-mediated reversion of its Y223-Nef to wild
type Nef the macaques demonstrated non-progressor or slow-
progressor phenotypes [75]. This might indicate a need for MHC-I
downregulation in the acute phase of the infection [75].
In both studies the mutated Nef ’s ability to downregulate MHC-I
molecules was regained via increased mutation rates facilitated by CTL
selective pressure. This increased rate of mutation to recover the MHC-
I downregulation function of Nef was so important that its recovery at
times occurred at the expense of its other functions such as the
downregulation of CD28 [75,76]. This demonstrates that the increase
in MHC-I modulation enables the virus to escape CTL detection and is
maintained in the presence of these cells [77].
Interestingly, the ability of HIV-1 Nef to downregulate MHC-I
changes during disease progression. MHC-I downregulation is 10- to
20-fold higher in immunocompetent (especially asymptomatic)
individuals compared to those that have progressed to AIDS [73]. In
AIDS patients the Nef protein’s functions are centred towards
increasing viral replication and infectivity, whilst increasing CD4
downregulation [73]. This is believed to be due to the high selective
pressure exerted by active CTLs in immunocompetent individuals,
which is lost when the immune system is destroyed and AIDS
progression has occurred [74].
Conclusion
In conclusion, Nef is a multifunctional pathogenicity factor
expressed by primate lentiviruses. Disruption of nef is associated with
defective viral replication. However the Nef protein has a wide range of
functions unrelated to infectivity of virions, some of those which are
directly related to immune evasion such as down modulation of CD4
[38,39], MHC-I [30,78] and to modulate the threshold of T cell
activation between T cells and macrophages [79,80].
The ability of Nef to interfere with the MHC-I complex is an
important virulence factor as it enables the HIV virus to evade the host
immune response. By selectively downregulating MHC-I HLA-A and
HLA-B, while maintaining the expression of HLA-C, HLA-E and
HLA-G HIV is able to evade both the innate response mediated by NK
cells and the adaptive immune response elicited by CTL effectors. This
protects the virus from immune recognition by both arms of the
immune response. Further research is needed to determine if any of
these pathways used in the downregulation of MHC-I can be safely
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inhibited for use as a therapeutic. Furthermore, determining the
percentage of long term non-progressors that exhibit CTLs that are
specific for HLA-C and HLA-E or NK cells that are specific for HLA-A
and HLA-B would also assist in determining the importance of the
selectivity in MHC-I downregulation and the possibility of these cells
being used as a means of prevention against HIV.
Although we have focused in this review on the function of Nef in
modulation of MHC-I proteins. It must not be forgotten that the Nef
protein can target a range of other immune signalling proteins e.g.,
TCR and CD3 as well as the costimulatory receptor CD28 that would
effectively block naïve T cell activation. So the HIV virus has a range of
weapons in its arsenal to intervene with cellular function and more
widely to target specific aspects of cell biology that are going to make it
conducive for viral replication and to avoid immune recognition.
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